Automated prostate cancer detection using T2-weighted and high-b-value diffusion-weighted magnetic resonance imaging - Abstract

PURPOSE: The authors propose a computer-aided diagnosis (CAD) system for prostate cancer to aid in improving the accuracy, reproducibility, and standardization of multiparametric magnetic resonance imaging (MRI).

METHODS: The proposed system utilizes two MRI sequences [T2-weighted MRI and high-b-value (b = 2000 s/mm2) diffusion-weighted imaging (DWI)] and texture features based on local binary patterns. A three-stage feature selection method is employed to provide the most discriminative features. The authors included a total of 244 patients. Training the CAD system on 108 patients (78 MR-positive prostate cancers and 105 benign MR-positive lesions), two validation studies were retrospectively performed on 136 patients (68 MR-positive prostate cancers, 111 benign MR-positive lesions, and 117 MR-negative benign lesions).

RESULTS: In distinguishing cancer from MR-positive benign lesions, an area under receiver operating characteristic curve (AUC) of 0.83 [95% confidence interval (CI): 0.76-0.89] was achieved. For cancer vs MR-positive or MR-negative benign lesions, the authors obtained an AUC of 0.89 AUC (95% CI: 0.84-0.93). The performance of the CAD system was not dependent on the specific regions of the prostate, e.g., a peripheral zone or transition zone. Moreover, the CAD system outperformed other combinations of MRI sequences: T2W MRI, high-b-value DWI, and the standard apparent diffusion coefficient (ADC) map of DWI.

CONCLUSIONS: The novel CAD system is able to detect the discriminative texture features for cancer detection and localization and is a promising tool for improving the quality and efficiency of prostate cancer diagnosis.

Written by:
Kwak JT, Xu S, Wood BJ, Turkbey B, Choyke PL, Pinto PA, Wang S, Summers RM.   Are you the author?
Center for Interventional Oncology, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892; Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892; Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892; Imaging Biomarkers and Computer-Aided Diagnosis Laboratory, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892.


Reference: Med Phys. 2015 May;42(5):2368.
doi: 10.1118/1.4918318

PubMed Abstract
PMID: 25979032 Prostate Cancer Section


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.